Asset Details
Do you wish to reserve the book?
Personalizing Diabetes Management in Liver Transplant Recipients: The New Era for Optimizing Risk Management
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Personalizing Diabetes Management in Liver Transplant Recipients: The New Era for Optimizing Risk Management
Do you wish to request the book?
Personalizing Diabetes Management in Liver Transplant Recipients: The New Era for Optimizing Risk Management
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Personalizing Diabetes Management in Liver Transplant Recipients: The New Era for Optimizing Risk Management
2022
Overview
Post‐transplant diabetes mellitus (PTDM) is a significant contributor to morbidity and mortality in liver transplant recipients (LTRs). With concurrent comorbidities and use of various immunosuppression medications, identifying a safe and personalized regimen for management of PTDM is needed. There are many comorbidities associated with the post‐transplant course including chronic kidney disease, cardiovascular disease, allograft steatosis, obesity, and de novo malignancy. Emerging data suggest that available diabetes medications may carry beneficial or, in some cases, harmful effects in the setting of these co‐existing conditions. Sodium‐glucose co‐transporter 2 inhibitors and glucagon‐like peptide 1 receptor agonists have shown the most promising beneficial results. Although there is a deficiency of LTR‐specific data, they appear to be generally safe. Effects of other medications are varied. Metformin may reduce the risk of malignancy. Pioglitazone may be harmful in patients combatting obesity or heart failure. Insulin may exacerbate obesity and increase the risk of developing malignancy. This review thoroughly discusses the roles of these extra‐glycemic effects and safety considerations in LTRs. Through weighing the risks and benefits, we conclude that alternatives to insulin should be strongly considered, when feasible, for personalized long‐term management based on risk factors and co‐morbidities.
Publisher
Wolters Kluwer Health Medical Research, Lippincott Williams & Wilkins,John Wiley and Sons Inc,Wolters Kluwer Health/LWW
Subject
/ Diabetes
/ Diabetes Mellitus, Type 2 - drug therapy
/ Etiology
/ Glucagon
/ Glucose
/ Humans
/ Hypoglycemic Agents - adverse effects
/ Insulin
/ Kidney Transplantation - adverse effects
/ Liver Transplantation - adverse effects
/ Obesity
/ Peptides
/ Review
